<h3>提升您的投资策略：</h3>
<ul>
<li>享受 TipRanks Premium 50% 的折扣！解锁强大的投资工具、先进的数据和专家分析师的见解，帮助您自信投资。</li>
</ul>
<p>Dimerix Limited（（AU:DXB））发布了更新。</p>
<p>Dimerix Limited 报告称，普通业务收入显著增长，较上年增长 914%，达到 590 万美元，截止至 2025 年 6 月 30 日。尽管收入增长，公司仍录得 1325 万美元的亏损，较去年亏损改善 22%。在此期间，公司未宣派任何股息。这一财务表现反映了 Dimerix 在其产品开发管道上的持续投资，这对其在生物技术行业的长期战略定位至关重要。</p>
<p>（AU:DXB）股票的最新分析师评级为买入，目标价为 1.58 澳元。要查看 Dimerix Limited 股票的完整分析师预测列表，请参见 AU:DXB 股票预测页面。</p>
<p><strong>关于 Dimerix Limited 的更多信息</strong></p>
<p>Dimerix Limited 在生物技术行业运营，专注于药品的开发。公司参与各种医疗条件的治疗研究与开发，特别强调肾脏疾病和其他慢性疾病。</p>
<p><strong>平均交易量：</strong> 1,603,583</p>
<p><strong>技术情绪信号：</strong> 买入</p>
<p><strong>当前市值：</strong> 2.821 亿澳元</p>
<p>在 TipRanks 的股票分析页面了解更多关于 DXB 股票的信息。</p>
<h2>热门文章：</h2>
<ul>
<li>RDDT 诉讼警报！针对 Reddit, Inc. 的集体诉讼</li>
<li>‘英伟达在高标准下表现最佳，’ TD Cowen 在第二季度财报前上调目标价</li>
<li>IRBT 诉讼警报！针对 iRobot Corporation 的集体诉讼</li>
</ul>
<p>免责声明与披露报告问题</p>

<p>Dimerix Limited (AU:DXB) 报告截至 2025 年 6 月 30 日的财年收入增长 914%，达到 590 万美元，尽管亏损为 1325 万美元，但较去年改善了 22%。该公司未宣布分红，并继续投资于其生物技术领域的产品开发管道。分析师将该股票评级为 “买入”，目标价为 1.58 澳元。Dimerix 专注于开发肾脏疾病和其他慢性病的治疗方案</p>

<h3>Elevate Your Investing Strategy:</h3>
<div class="lb-trans"><h3>提升您的投资策略：</h3>
</div><ul>
<li>Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.</li>
</ul>
<div class="lb-trans"><ul>
<li>享受 TipRanks Premium 50% 的折扣！解锁强大的投资工具、先进的数据和专家分析师的见解，帮助您自信投资。</li>
</ul>
</div><p>Dimerix Limited ( (AU:DXB) ) has issued an update.</p>
<div class="lb-trans"><p>Dimerix Limited（（AU:DXB））发布了更新。</p>
</div><p>Dimerix Limited reported a significant increase in revenues from ordinary activities, up 914% to $5.9 million for the year ended June 30, 2025. Despite this revenue growth, the company recorded a loss of $13.25 million, which is a 22% improvement from the previous year’s loss. The company did not declare any dividends during this period. This financial performance reflects Dimerix’s ongoing investment in its product development pipeline, which is crucial for its long-term strategic positioning in the biotechnology sector.</p>
<div class="lb-trans"><p>Dimerix Limited 报告称，普通业务收入显著增长，较上年增长 914%，达到 590 万美元，截止至 2025 年 6 月 30 日。尽管收入增长，公司仍录得 1325 万美元的亏损，较去年亏损改善 22%。在此期间，公司未宣派任何股息。这一财务表现反映了 Dimerix 在其产品开发管道上的持续投资，这对其在生物技术行业的长期战略定位至关重要。</p>
</div><p>The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.58 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.</p>
<div class="lb-trans"><p>（AU:DXB）股票的最新分析师评级为买入，目标价为 1.58 澳元。要查看 Dimerix Limited 股票的完整分析师预测列表，请参见 AU:DXB 股票预测页面。</p>
</div><p><strong>More about Dimerix Limited</strong></p>
<div class="lb-trans"><p><strong>关于 Dimerix Limited 的更多信息</strong></p>
</div><p>Dimerix Limited operates in the biotechnology industry, focusing on the development of pharmaceutical products. The company is involved in the research and development of therapies for various medical conditions, with a particular emphasis on kidney disease and other chronic ailments.</p>
<div class="lb-trans"><p>Dimerix Limited 在生物技术行业运营，专注于药品的开发。公司参与各种医疗条件的治疗研究与开发，特别强调肾脏疾病和其他慢性疾病。</p>
</div><p><strong>Average Trading Volume:</strong> 1,603,583</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 1,603,583</p>
</div><p><strong>Technical Sentiment Signal:</strong> Buy</p>
<div class="lb-trans"><p><strong>技术情绪信号：</strong> 买入</p>
</div><p><strong>Current Market Cap:</strong> A$282.1M</p>
<div class="lb-trans"><p><strong>当前市值：</strong> 2.821 亿澳元</p>
</div><p>Learn more about DXB stock on TipRanks’ Stock Analysis page.</p>
<div class="lb-trans"><p>在 TipRanks 的股票分析页面了解更多关于 DXB 股票的信息。</p>
</div><h2>Trending Articles:</h2>
<div class="lb-trans"><h2>热门文章：</h2>
</div><ul>
<li>RDDT Lawsuit Alert! Class Action Lawsuit Against Reddit, Inc.</li>
<li>‘Nvidia Is Best Positioned to Clear a High Bar,’ Says TD Cowen as it Raises PT Ahead of Q2 Print</li>
<li>IRBT Lawsuit Alert! Class Action Lawsuit Against iRobot Corporation</li>
</ul>
<div class="lb-trans"><ul>
<li>RDDT 诉讼警报！针对 Reddit, Inc. 的集体诉讼</li>
<li>‘英伟达在高标准下表现最佳，’ TD Cowen 在第二季度财报前上调目标价</li>
<li>IRBT 诉讼警报！针对 iRobot Corporation 的集体诉讼</li>
</ul>
</div><p>Disclaimer &amp; DisclosureReport an Issue</p>
<div class="lb-trans"><p>免责声明与披露报告问题</p>
</div>

尽管存在亏损，Dimerix Limited 报告了显著的收入增长